Literature DB >> 22699851

Metals, membranes, and amyloid-β oligomers: key pieces in the Alzheimer's disease puzzle?

Andrew D Watt1, Victor L Villemagne, Kevin J Barnham.   

Abstract

Over the past 100 years, there has been an exponential increase in our understanding of the underlying pathology of Alzheimer's disease (AD). This growth in knowledge has largely stemmed from the intensification of research into AD which has occurred over the past three decades and the incorporation of the amyloid cascade hypothesis as the generally accepted dogma of AD pathogenesis. While at times contentious, the notion that AD arises from aberrations in amyloid-β (Aβ) production and degradation has led to a number of significant breakthroughs in the way in which AD is currently diagnosed and in the attempts at disease modifying therapies, from investigations into the underlying factors mediating the aggregation of Aβ to the development of therapeutic strategies and measures of neuroimaging allowing Aβ burden to be monitored within the AD-affected brain. This review focuses on some of the recent work we have conducted toward elucidating the role of Aβ in AD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22699851     DOI: 10.3233/JAD-2012-129017

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  10 in total

Review 1.  The rationale for deep brain stimulation in Alzheimer's disease.

Authors:  Zaman Mirzadeh; Ausaf Bari; Andres M Lozano
Journal:  J Neural Transm (Vienna)       Date:  2015-10-06       Impact factor: 3.575

Review 2.  Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis.

Authors:  Kirsten L Viola; William L Klein
Journal:  Acta Neuropathol       Date:  2015-01-22       Impact factor: 17.088

Review 3.  Naturally Occurring Antioxidant Therapy in Alzheimer's Disease.

Authors:  Andrila E Collins; Tarek M Saleh; Bettina E Kalisch
Journal:  Antioxidants (Basel)       Date:  2022-01-23

4.  Minor Structural Variations of Small Molecules Tune Regulatory Activities toward Pathological Factors in Alzheimer's Disease.

Authors:  Michael W Beck; Jeffrey S Derrick; Jong-Min Suh; Mingeun Kim; Kyle J Korshavn; Richard A Kerr; Woo Jong Cho; Scott D Larsen; Brandon T Ruotolo; Ayyalusamy Ramamoorthy; Mi Hee Lim
Journal:  ChemMedChem       Date:  2017-10-09       Impact factor: 3.466

Review 5.  Assessment of potential targets for deep brain stimulation in patients with Alzheimer's disease.

Authors:  Mayur Sharma; Milind Deogaonkar; Ali Rezai
Journal:  J Clin Med Res       Date:  2015-05-08

Review 6.  The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade.

Authors:  Erika N Cline; Maíra Assunção Bicca; Kirsten L Viola; William L Klein
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

7.  A catalytic antioxidant for limiting amyloid-beta peptide aggregation and reactive oxygen species generation.

Authors:  Luiza M F Gomes; Atif Mahammed; Kathleen E Prosser; Jason R Smith; Michael A Silverman; Charles J Walsby; Zeev Gross; Tim Storr
Journal:  Chem Sci       Date:  2018-12-03       Impact factor: 9.825

8.  Modification of Aβ Peptide Aggregation via Covalent Binding of a Series of Ru(III) Complexes.

Authors:  Luiza M F Gomes; Janaina C Bataglioli; Allison J Jussila; Jason R Smith; Charles J Walsby; Tim Storr
Journal:  Front Chem       Date:  2019-12-03       Impact factor: 5.221

Review 9.  Metal and complementary molecular bioimaging in Alzheimer's disease.

Authors:  Nady Braidy; Anne Poljak; Christopher Marjo; Helen Rutlidge; Anne Rich; Tharusha Jayasena; Nibaldo C Inestrosa; Perminder Sachdev
Journal:  Front Aging Neurosci       Date:  2014-07-15       Impact factor: 5.750

Review 10.  Transient dynamics of Aβ contribute to toxicity in Alzheimer's disease.

Authors:  E Hubin; N A J van Nuland; K Broersen; K Pauwels
Journal:  Cell Mol Life Sci       Date:  2014-05-07       Impact factor: 9.261

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.